tirzepatide cardiovascular outcomes An Observational Study of of vs Glucagon-Like Peptide-1 Receptor Agonists Risk of major adverse cardiovascular

28:591-598 [PMC free article: PMC8938269] [PubMed: 35210595] 399

[1] Your doctor will also want to know about recent changes in weight, appetite, or mood , as these may influence treatment decisions

The choice depends on the individual's diabetes control, previous treatment response, and specific clinical circumstances

Safety assessments included adverse events, hypoglycemic episodes, injection site reactions, vital signs, physical examination, clinical laboratory assessments and ECG

There are hormones related to body weight regulation that follow a healthy circadian rhythm, says Kumar, referring to the body processes of sleeping and waking that follow a 24-hour cycle

GLP-1 medications help the body regulate blood sugar and slow gastric emptying